Tag: pipeline

CIQ expands Fuzzball to full multi-cloud so AI and HPC teams ship faster and spend less, with absolute workflow reproducibility and portability

Fuzzball intelligently meta-orchestrates AI and HPC workloads across CoreWeave, AWS, GCP, OCI, Azure and on-premises infrastructure from one control planeRENO, Nev., June 4, 2026...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

X-energy Reports First Quarter 2026 Results

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi launches 2026 global employee stock purchase plan

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

June 4, 2026

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Tennessee American Water Proudly Recognizes American Water Charitable Foundation 2026 Water and Environment Grantees

Top Two Spots in American Banker’s 50 Top Innovators in Finance Awarded to CEOs of Vantage Bank and Custodia, Hazel Network’s Co-Founders

Vinitaly debuts in Cape Town to strengthen Italian wine presence in Africa

CIQ expands Fuzzball to full multi-cloud so AI and HPC teams ship faster and spend less, with absolute workflow reproducibility and portability

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

X-energy Reports First Quarter 2026 Results

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

Press Release: Sanofi launches 2026 global employee stock purchase plan

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

/C O R R E C T I O N — Oberland Biotech GmbH/

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us